Abciximab
Severe
Database
Clinical effect not specified
Source: DDInter
Drug reference
vorapaxar
Protease-activated receptor-1 (PAR-1) inhibitor · Antiplatelet
Protease-activated receptor-1 (PAR-1) inhibitorAntiplatelet
CDSCO approved
EXCRETION
—
not curated
INTERACTIONS
12 major
SEVERE in our sources
PREGNANCY
—
not curated
Top interactionssee all 12 →
- AbciximabSevereDatabaseDDInter
- AcalabrutinibSevereDatabaseDDInter
- AlteplaseSevereDatabaseDDInter
- AmprenavirSevereDatabaseDDInter
Mechanism
Not yet extracted
Indications
reduction of thrombotic cardiovascular events in patients with a history of myocardial infarction or peripheral artery diseasesecondary prevention in patients with a history of myocardial infarction or peripheral artery disease
Dosing
- Adult
- Given orally in combination with either aspirin or clopidogrel.
Pharmacokinetics
Onset
rapid onset of action
Duration
effect on thrombin-induced platelet aggregation can persist for up to 4 weeks after the drug is stopped (due to tight binding to PAR-1)
Half-life
3 to 4 days (circulating)
Bioavailability
90%
Metabolism
metabolized in the liver by CYP3A4
Contraindications
- history of intracranial bleeding
- stroke
- transient ischemic attack
- cerebrovascular disease
- prior intracranial bleed
Side effects
Common
bleeding (increased risk)
Serious
- Bleeding
- Intracranial bleeding (doubled risk compared to placebo)
- Moderate or severe bleeding
Drug interactions
Acalabrutinib
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Alteplase
Severe
Database
Clinical effect not specified
Source: DDInter
Amprenavir
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Anagrelide
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Anisindione
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Anistreplase
Severe
Database
Clinical effect not specified
Source: DDInter
Antithrombin Alfa
Severe
Database
Clinical effect not specified
Source: DDInter
Antithrombin Iii Human
Severe
Database
Clinical effect not specified
Source: DDInter
Apalutamide
Severe
Database
Drug interaction classified as: metabolism
Source: DDInter
Apixaban
Severe
Database
Drug interaction classified as: synergy
Source: DDInter
Ardeparin
Severe
Database
Clinical effect not specified
Source: DDInter
Related guidelines
Ask House about vorapaxar
Continue into a citation-backed clinical answer with the drug context already attached.
Sources: Goodman & Gilman 14e, Harrison 22e·Verified: 2026-05-10 · House clinical team